Posts Tagged ‘Brinavess’

September 26th, 2012

Merck Returns to Cardiome All Rights to Atrial Fibrillation Drug Vernakalant

Merck and Cardiome announced today that Merck is returning to Cardiome all marketing and development rights for the atrial fibrillation (AF) drug vernakalant. An intravenous formulation of vernakalant is marketed in Europe as Brinavess. It has not been approved in the United States, though it received a positive recommendation from the FDA’s Cardiovascular and Renal […]